Closed.
Ysotope Theranostics no longer appears in the directory or on the maps; its funding history is kept below.
Source ↗
Ysotope Theranostics was a Spanish deep-tech biotech spin-off of the Vall d'Hebron Institut de Recerca (VHIR) that designed and validated targeted radiopharmaceuticals for precision oncology, notably PET radiotracers built from antibodies and biosimilars to image and track CAR-T cells in patients. Founded in April 2022 in Barcelona and accelerated by Lanzadera (Marina de Empresas, Valencia), it worked on a co-development and licensing model with R&D partners and raised a first €150,000 round from Biozell Ventures in March 2023, with a planned follow-on of ~€450,000. Ysotope Theranostics SL (CIF B09958760) is registered as 'extinguida' following a voluntary insolvency proceeding (Concurso Voluntario 38/2025, Juzgado de lo Mercantil nº 3 de Barcelona) published 10-17 November 2025.
A VC-backed radiopharmaceutical biotech that develops targeted radionuclide theranostics for oncology and partners them through co-development and supply deals.
A venture-funded developer of targeted radiopharmaceuticals for cancer that paired imaging agents with therapies, and was bought by BMS, a typical licensing or acquisition exit.
The closest match: it builds antibody-fragment PET radiotracers that image CD8 T-cells, used to track immunotherapy and cell therapy in patients, and it earns money by licensing and partnering them with pharma.
I
R
A
A
I
